252 projects, none clinically valuable, several harmful.
Any OpenAI angles they missed?
1 Like
You would think so! But if 250 teams try to use a tool in a crisis and none succeeds, you have to wonder if there’s a little excess optimism.
But the article doesn’t cover the other areas where machine learning/AL has undoubtedly played a major role in successful response to the pandemic, e.g. pharma and logistics.
1 Like
Meh. Everyone was scrambling for the best possible solution and none of them went through regulatory bodies like the FDA or its counterparts in the EU. It’s incredibly irresponsible to prematurely declare these tools as “unfit for clinical use”. I hadn’t realized the MIT Technology Review had stooped to Buzzfeed level clickbait.
1 Like